Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 10,348 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $93,545.92. Following the transaction, the insider owned 332,412 shares in the company, valued at $3,005,004.48. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ocular Therapeutix Stock Performance

OCUL traded down $1.89 during midday trading on Tuesday, reaching $6.99. The company had a trading volume of 51,503,167 shares, compared to its average volume of 4,346,415. The business has a 50-day moving average of $11.22 and a two-hundred day moving average of $11.78. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. Ocular Therapeutix, Inc. has a 1 year low of $5.78 and a 1 year high of $16.44. The company has a market cap of $1.52 billion, a P/E ratio of -4.85 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The company had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. During the same period in the previous year, the company posted ($0.29) EPS. The firm’s revenue was down 22.4% on a year-over-year basis. As a group, equities research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OCUL shares. Chardan Capital reiterated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday. HC Wainwright boosted their price target on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Ocular Therapeutix in a research note on Monday, December 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC lifted its holdings in shares of Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,392 shares during the period. Hilton Head Capital Partners LLC purchased a new stake in Ocular Therapeutix in the 4th quarter worth about $42,000. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix in the fourth quarter worth about $61,000. Finally, KBC Group NV purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $78,000. Institutional investors own 59.21% of the company’s stock.

Trending Headlines about Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.